Edition:
India

Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

127.81USD
26 Apr 2018
Change (% chg)

$-1.71 (-1.32%)
Prev Close
$129.52
Open
$129.51
Day's High
$130.04
Day's Low
$127.75
Volume
46,337
Avg. Vol
344,776
52-wk High
$143.22
52-wk Low
$100.20

Select another date:

Wed, Apr 25 2018

UPDATE 2-Edward Lifesciences' heart valve sales in Europe disappoint, shares fall

April 24 Edwards Lifesciences Corp's first-quarter sales for transcatheter heart valves missed Wall Street targets on Tuesday, as the medical device maker lost market share in Europe to its rival, Medtronic Plc.

BRIEF-Edwards Lifesciences Reports Q1 Earnings Of $0.96/Share

* QUARTERLY TOTAL ADJUSTED SALES $937.5 MILLION, UP 9.3 PERCENT

Edwards Lifesciences reports 1.3 pct rise in quarterly sales

April 24 Medical device maker Edwards Lifesciences Corp reported a 1.3 percent rise in first-quarter revenue on Tuesday on higher demand for transcatheter heart valves, its biggest business.

BRIEF-Boston Scientific Prevails In European Patent Dispute With Edwards Lifesciences

* BOSTON SCIENTIFIC PREVAILS IN EUROPEAN PATENT DISPUTE WITH EDWARDS LIFESCIENCES

BRIEF-Edwards Lifesciences Corp Says CEO Michael Mussallem's FY 2017 Total Compensation Was $10.8 Mln Vs $9.7 Mln In FY 2016

* EDWARDS LIFESCIENCES CORP SAYS CEO MICHAEL MUSSALLEM'S FY 2017 TOTAL COMPENSATION WAS $10.8 MILLION VERSUS $9.7 MILLION IN FY 2016 - SEC FILING Source text: (https://bit.ly/2GUuNcF) Further company coverage:

BRIEF-Boston Scientific says co prevails in UK Edwards Lifesciences Litigation​

* BOSTON SCIENTIFIC CORP SAYS ‍BOSTON SCIENTIFIC PREVAILS IN U.K. EDWARDS LIFESCIENCES LITIGATION​

BRIEF-Edwards Lifesciences Prevails In U.S. Patent Office Review

* EDWARDS PREVAILS IN U.S. PATENT OFFICE REVIEW THAT FINDS BOSTON SCIENTIFIC TRANSCATHETER VALVE PATENT CLAIMS INVALID Source text for Eikon: Further company coverage:

BRIEF-Edwards Completes Enrollment In Partner 3 Low-Risk CT Sub-Study

* EDWARDS COMPLETES ENROLLMENT IN PARTNER 3 LOW-RISK CT SUB-STUDY, UPDATES TIMELINE FOR SAPIEN 3 ULTRA SYSTEM LAUNCH IN EUROPE

BRIEF-Edwards Lifesciences Says FDA Grants De Novo Request For Acumen Hypotension Prediction Index Software​

* EDWARDS LIFESCIENCES CORP - ‍U.S. FDA GRANTED DE NOVO REQUEST FOR EDWARDS' ACUMEN HYPOTENSION PREDICTION INDEX SOFTWARE​ Source text for Eikon: Further company coverage:

BRIEF-Edwards Says Its Self-Expanding Transcatheter Heart Valve Receives CE Mark

* GOT CE MARK FOR SELF-EXPANDING CENTERA VALVE FOR SEVERE, SYMPTOMATIC AORTIC STENOSIS PATIENTS AT HIGH RISK OF OPEN-HEART SURGERY

Select another date: